![]() ![]() Analysts expect adjusted earnings to reach $5.472 per share for the current fiscal year. Year-over-year quarterly sales growth most recently was -7.1%. Horizon Therapeutics PLC’s trailing 12-month revenue is $3.6 billion with a 14.4% profit margin. Latest Horizon Therapeutics PLC Stock NewsĪs of April 21, 2023, Horizon Therapeutics PLC had a $25.5 billion market capitalization, putting it in the 94th percentile of companies in the Pharmaceuticals industry.Ĭurrently, Horizon Therapeutics PLC’s price-earnings ratio is 50.2. Read on to find out how ( HZNP) grades on certain investment factors and determine whether it meets your investment needs. The company has a quick ratio of 3.67, a current ratio of 3.85 and a debt-to-equity ratio of 0.50.Learn more about whether Horizon Therapeutics PLC is a good stock to buy or sell based on recent news as well as its key financial metrics. The business's fifty day simple moving average is $109.99 and its two-hundred day simple moving average is $93.31. The firm has a market cap of $24.88 billion, a price-to-earnings ratio of 48.83, a PEG ratio of 3.95 and a beta of 1.15. Horizon Therapeutics Public has a twelve month low of $57.84 and a twelve month high of $117.49. HZNP stock opened at $108.89 on Thursday. Horizon Therapeutics Public Stock Performance According to data from MarketBeat, Horizon Therapeutics Public currently has an average rating of "Hold" and a consensus target price of $111.42. Eight equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Finally, Guggenheim cut Horizon Therapeutics Public from a "buy" rating to a "neutral" rating and upped their target price for the stock from $98.00 to $116.50 in a report on Tuesday, December 13th. BMO Capital Markets downgraded Horizon Therapeutics Public from an "outperform" rating to a "market perform" rating in a report on Tuesday, December 13th. Jefferies Financial Group increased their price objective on Horizon Therapeutics Public from $101.00 to $125.00 in a research note on Thursday, December 1st. assumed coverage on shares of Horizon Therapeutics Public in a research note on Sunday. SVB Leerink downgraded shares of Horizon Therapeutics Public from an "outperform" rating to a "market perform" rating and raised their price target for the stock from $88.00 to $116.50 in a research note on Tuesday, December 13th. Several other research analysts also recently commented on the stock. During the same quarter in the prior year, the firm posted $1.41 earnings per share. The business's revenue for the quarter was down 7.1% on a year-over-year basis. Horizon Therapeutics Public had a net margin of 14.37% and a return on equity of 23.04%. The business had revenue of $942.03 million for the quarter, compared to the consensus estimate of $922.95 million. The biopharmaceutical company reported $1.21 earnings per share for the quarter, beating the consensus estimate of $1.09 by $0.12. Horizon Therapeutics Public ( NASDAQ:HZNP - Get Rating) last announced its earnings results on Wednesday, March 1st. Oppenheimer also issued estimates for Horizon Therapeutics Public's Q2 2023 earnings at $1.13 EPS, Q3 2023 earnings at $1.17 EPS, Q4 2023 earnings at $1.23 EPS, FY2023 earnings at $4.65 EPS, FY2024 earnings at $5.88 EPS and FY2025 earnings at $6.60 EPS. The consensus estimate for Horizon Therapeutics Public's current full-year earnings is $5.53 per share. Gershell expects that the biopharmaceutical company will earn $1.12 per share for the quarter. Horizon Therapeutics Public Limited ( NASDAQ:HZNP - Get Rating) - Analysts at Oppenheimer issued their Q1 2023 EPS estimates for shares of Horizon Therapeutics Public in a report released on Monday, March 27th. Horton Shares Raise The Roof, Or Is This The Ceiling? Healthcare Sector: Overview and Keys to Investing.Genuine Parts Company Is Genuinely A Good Buy.Finding New Technology to Invest in: A Guide.Why Philip Morris May Continue to Beat the Broader Market?.Netflix Increases Buybacks: Can It Complete A Reversal In 2023?.AutoNation's Plans are Keeping Analysts Around.Proctor & Gamble Is Going To Set A New High.2 Industrial Strength Dividend Stocks Melting Up.MarketBeat Week in Review – 4/17 - 4/21. ![]()
0 Comments
Leave a Reply. |